{"id":"W3136856529","doi":"10.1158/1538-7445.sabcs20-pd3-03","title":"Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Oncology; Breast cancer; Internal medicine; Trastuzumab; Hazard ratio; Placebo; Stage (stratigraphy); Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009007624,0.001265824,0.002040657,0.0003345786,0.0003268743,0.001540178,0.001083603,0.0009793027,0.004297337],"category_scores_gemma":[0.005152254,0.0003685981,0.004460373,0.0005744387,0.0008362955,0.001270181,0.0008854417,0.002626442,0.0005687515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009029292,"about_ca_system_score_gemma":0.001253864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000439533,"about_ca_topic_score_gemma":0.001143615,"domain_scores_codex":[0.9967991,0.002064694,0.000258602,0.0003984086,0.0002838787,0.0001952658],"domain_scores_gemma":[0.9972892,0.0008142582,0.0007655685,0.0003777603,0.0002541841,0.0004990527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9663417,0.001852933,0.005458361,0.0005100697,0.005176828,0.0000593427,0.0000420291,0.001377539,0.001828496,0.0001975808,0.00212361,0.01503152],"study_design_scores_gemma":[0.8617948,0.09089092,0.02972453,0.0001419644,0.007510497,0.0002385219,0.00007011461,0.002262489,0.001945987,0.001084312,0.0042664,0.00006951366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9715108,0.006171326,0.0024505,0.001075941,0.0003139983,0.00359268,0.01013082,0.0001938735,0.004560005],"genre_scores_gemma":[0.9826396,0.0008960563,0.001844141,0.001071612,0.000210499,0.002497519,0.009184748,0.00004562491,0.001610207],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009007624,"threshold_uncertainty_score":0.0476374,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04989331607234977,"score_gpt":0.4014012699091703,"score_spread":0.3515079538368205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}